当前位置： SCI文献检索 > Therapeutic Innovation & Regulatory Science期刊下所有文献 > Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients' Access to Medicines.

Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients' Access to Medicines.

Abstract：

BACKGROUND:Timely access to new medicines may be addressed through strengthening of registration efficiencies and timelines by establishing and refining value-added registration processes, resources, and systems. The aims of this study were to evaluate the timelines of the milestones of the South African review process and the overall approval process for new active substances (NASs) in 2015-2018 and to provide recommendations for improved patients' access to new medicines through timely registration. METHODS:Data identifying the milestones and overall approval times for NASs registered by the South African Agency during 2015-2018 were collected and analyzed. RESULTS:The most NASs (42) were approved in 2017 and the least (15) in 2018. The shortest median approval time (1218 calendar days) was achieved in 2015 and the longest (2124 days), in 2018. All applications were reviewed using the full review process, and 16/99 (16%) were assigned priority status and were reviewed and approved through the fast track review. CONCLUSIONS:While the extensive delays in NASs approvals in South Africa may be attributed to inefficient operational processes, resource constraints, and as an increased number of applications for registration, the newly established South African Heath Products Regulatory Agency has re-engineered and streamlined its regulatory review process, which has been piloted and will be enhanced prior to final implementation. Among recommendations for improvement, SAHPRA should consider measurement and monitoring of milestones, facilitated regulatory pathways, implementing a reliance strategy, and a quality management system.

journal_name

Ther Innov Regul Sci

journal_title

Therapeutic innovation & regulatory science

authors

Keyter A,Salek S,Gouws J,Banoo S,Walker S

doi

10.1007/s43441-019-00013-5

subject

Has Abstract

pub_date

2020-07-01 00:00:00

pages

878-887

issue

4

eissn

2168-4790

issn

2168-4804

pii

10.1007/s43441-019-00013-5

journal_volume

54

pub_type

杂志文章

相关文献

Therapeutic Innovation & Regulatory Science文献大全
  • Complex Generic Products: Insight of Current Regulatory Frameworks in US, EU and Canada and the Need of Harmonisation.

    abstract：:The regulatory agencies all over the world have defined the pathway and regulations for the approval of simple small-molecule generics. In addition, the agencies are striving to form perspicuous regulatory frameworks for the approval of biosimilars. In this view, there are no defined regulations for the approval of co...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章,评审

    doi：10.1007/s43441-020-00114-6

    authors： Lunawat S,Bhat K

    更新日期：2020-09-01 00:00:00

  • Baseline Assessment of the Evolving 2017 eClinical Landscape.

    abstract：:The volume and diversity of data collected to support each clinical study has increased dramatically in response to the rising scope and complexity of global drug development programs. The Tufts Center for the Study of Drug Development conducted an online survey of 257 unique global companies-77% drug development spon...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479018769292

    authors： Wilkinson M,Young R,Harper B,Machion B,Getz K

    更新日期：2019-01-01 00:00:00

  • Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.

    abstract：BACKGROUND:In the breakthrough therapy designation (BTD) and Sakigake designation programs, rolling submission and close communication between applicants and regulatory authorities enable the timely access of patients to innovative medicines. However, challenges in the quality development, including chemistry, manufact...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-019-00019-z

    authors： Kajiwara E,Shikano M

    更新日期：2020-07-01 00:00:00

  • Lessons Learned From Hundreds of Thorough QT Studies.

    abstract：BACKGROUND:The coherence between the relationship of QTc and drug plasma concentration (this relationship is measured through the slope) and ICH E14 findings based on hundreds of QT study reports was studied. RESULTS:Based on ICH E14 analysis, our findings indicate that if the slope was not positive, in most cases (86...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479014563549

    authors： Zhang J,Chen H,Tsong Y,Stockbridge N

    更新日期：2015-05-01 00:00:00

  • Advancing Drug Safety Through Prospective Pharmacovigilance.

    abstract：:Much has changed in a relatively short period of time. There is a raging debate over the level of evidence expected to first introduce a treatment to patients based on smaller, more adaptive data sets. Some argue for less data followed by postapproval follow-up, others for more adaptive clinical trial designs and end-...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 社论

    doi：10.1177/2168479018766887

    authors： Pitts PJ,Le Louet H

    更新日期：2018-07-01 00:00:00

  • Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation.

    abstract：:After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the guidance of the European Medicines Agency in 2014. Althoug...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015618697

    authors： Schulthess D,Baird LG,Trusheim M,Unger TF,Lumpkin M,Hoos A,Garner S,Gavin P,Goldman M,Seigneuret N,Chlebus M,Van Baelen K,Bergstrom R,Hirsch G

    更新日期：2016-05-01 00:00:00

  • Evaluation and Characterization of Health Economics and Outcomes Research in SAARC Nations.

    abstract：OBJECTIVE:To identify, evaluate, and characterize the variety, quality, and intent of the health economics and outcomes research studies being conducted in SAARC (South Asian Association for Regional Cooperation) nations. METHODS:Studies published in English language between 1990 and 2015 were retrieved from Medline d...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章,评审

    doi：10.1177/2168479017731583

    authors： Mehta M,Nerurkar R

    更新日期：2018-05-01 00:00:00

  • ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder.

    abstract：:Attention deficit hyperactivity disorder (ADHD) is the most common neurobiological disorder in children, with a prevalence of ~6-7%1,2 that has remained stable for decades2. The social and economic burden associated with patients3, families, and broader systems (healthcare/educational) is substantial, with the annual ...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015599811

    authors： Connolly JJ,Glessner JT,Elia J,Hakonarson H

    更新日期：2015-09-01 00:00:00

  • New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels.

    abstract：BACKGROUND:The FDA Patient-Focused Drug Development Initiative was launched to ensure the incorporation of the patient voice into drug development and evaluation. Since 2017, the FDA must publish a statement outlining patient experience data (PED) considered in the approval of new drugs. This study investigated the pre...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00244-x

    authors： Schultz-Knudsen K,Sabaliauskaite U,Hellsten J,Lassen AB,Morant AV

    更新日期：2020-11-23 00:00:00

  • Technology Considerations to Enable the Risk-Based Monitoring Methodology.

    abstract：:TransCelerate BioPharma Inc developed a methodology based on the notion that shifting monitoring processes from an excessive concentration on source data verification to comprehensive risk-driven monitoring will increase efficiencies and enhance patient safety and data integrity while maintaining adherence to good cli...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479014546336

    authors： Barnes S,Katta N,Sanford N,Staigers T,Verish T

    更新日期：2014-09-01 00:00:00

  • A Framework for Managing the Minimal Clinically Important Difference in Clinical Trials.

    abstract：:There is a long history of discussions about what is a minimal clinically important difference (MCID) and how this term applies to clinical research. This paper deals with a practical framework for MCID and its applicability to clinical trials. A literature review on the topic confirmed the fundamental role of MCID fo...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479013487541

    authors： Koynova D,Lühmann R,Fischer R

    更新日期：2013-07-01 00:00:00

  • A Novel Collaborative Approach to Building Better Clinical Trials: New Insights From a Patient Engagement Workshop to Propel Patient-Centricity Forward.

    abstract：BACKGROUND:(1) A growing number of pharmaceutical and biotechnology organizations are engaging patients, their support networks, and clinical trial site staff at various touchpoints along the clinical research development spectrum to solicit feedback on how to reduce the burden of clinical trial participation and admin...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479019849875

    authors： Gregg A,Getz N,Benger J,Anderson A

    更新日期：2019-05-22 00:00:00

  • Interdisciplinary Safety Evaluation and Quantitative Safety Monitoring: Introduction to a Series of Papers.

    abstract：:The American Statistical Association and DIA have created an interdisciplinary working group of drug safety experts from academia, industry and regulatory backgrounds to explore the future direction for safety monitoring. This introduction to the series explains the background and rationale for this special section. ...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479018793130

    authors： Seltzer JH,Li J,Wang W

    更新日期：2019-03-29 00:00:00

  • Analyzing Upward Deviation of Actual vs Predicted Drug Sales in Japan for a Reasonable Drug-Pricing Policy.

    abstract：BACKGROUND:Predictions of drug sales play an important role in setting drug prices in Japan, where drug prices are highly regulated. One of 2 primary Japanese drug-pricing methodologies-the cost calculation method- refers extensively to the prediction of drug sales in establishing drug prices. Deviations from predicted...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479019860123

    authors： Shibata S,Fukumoto D,Suzuki T,Ozaki K

    更新日期：2019-07-16 00:00:00

  • Monitoring and Evaluating the Effect of Regulatory Action: Some Recent Case Studies.

    abstract：:Large electronic health care databases can be used to evaluate the effectiveness of regulatory action. Designing and interpreting such studies can be challenging. We demonstrate using case studies on modafinil, benzodiazepines, dosulepin, and piroxicam that measuring the impact of regulatory action is possible and can...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015570333

    authors： Thomson A,Meeraus WH,Wong J,Suvarna R

    更新日期：2015-07-01 00:00:00

  • Regulatory Definitions and Good Pharmacovigilance Practices in Social Media: Challenges and Recommendations.

    abstract：:Social media presents new challenges to the biopharmaceutical industry for conducting pharmacovigilance activities. The authors reviewed worldwide regulatory guidance documents related to monitoring of adverse events posted on social media sites and identified gaps in current regulatory definitions for pharmacovigilan...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015587362

    authors： Naik P,Umrath T,van Stekelenborg J,Ruben R,Abdul-Karim N,Boland R,Ibara M,Ekuta J,Washburn D,Stergiopoulos S

    更新日期：2015-11-01 00:00:00

  • Assessing the Quality of Database Search Strategies Utilized by Meta-analyses That Evaluate Infectious Disease Drug Therapy.

    abstract：:Meta-analyses are increasingly influencing clinical practice, but significant methodological flaws have been reported. The purpose of this study was to evaluate the quality of search strategies utilized by anti-infective meta-analyses. The Embase database was searched for meta-analyses evaluating anti-infective drug t...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479013516774

    authors： Marler JL,Curry KY,Suda KJ

    更新日期：2014-05-01 00:00:00

  • Strategic Shift of Statistical Review on Data Quality Assessment for New Drug Applications in China.

    abstract：:Data quality is critical for clinical trials to obtain robust conclusions about drug safety and efficacy evaluation. Effective data quality evaluation has been one of the major obstacles to new drug approvals in China, which hinders innovation in drug discovery and development ultimately. To improve the data quality s...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479018778528

    authors： Wang J,Wang G,Li M,Han J,Zeng X,Pan J,Yang J

    更新日期：2019-03-01 00:00:00

  • Product Registration in Developing Countries: A Proposal for an Integrated Regional Licensing System Among Countries in Regional Economic Blocs.

    abstract：:The product pipeline for diseases that disproportionately affect the developing world has considerably expanded over the last decade. Indeed, there are about 134 products for these diseases in the pipeline, including vaccines, drugs, diagnostics, microbicides, and vector control tools, and dozens of these products are...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479013478952

    authors： Saidu Y,De Angelis D,Aiolli S,Stefano G,Georges AM

    更新日期：2013-05-01 00:00:00

  • Community Opinions on the Collection and Use of Historical Control Data in Nonclinical Toxicity Studies.

    abstract：BACKGROUND:Access and use of historical control data was identified as a top stakeholder concern across organizations according to results of a survey of needs and challenges related to nonclinical data conducted by the FDA/PhUSE Nonclinical Working Group in 2011. There is a perception there may be additional ways to c...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015600203

    authors： Mihalcik LM,Bausman M,Brown P,Everds N,Feldmann J,Henck J,Potenta D,Sims J,Zandee J

    更新日期：2016-03-01 00:00:00

  • Differences in Clinical Research Perceptions and Experiences by Age Subgroup.

    abstract：BACKGROUND:(1) To assess the differing viewpoints of actual and potential adult clinical trial participants in 5 age cohorts, (2) identify misperceptions and opportunities to reduce unnecessary burdens on volunteers, and (3) provide age-specific feedback to study sponsors on their current engagement efforts. METHODS:B...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-019-00033-1

    authors： Anderson A,Borfitz D,Getz K

    更新日期：2020-01-01 00:00:00

  • Building a Better Approach for the Benefit of Patients: 10 Pillars to Strengthen Regulatory Review Systems Globally.

    abstract：:In the current pharmaceutical regulatory environment, patients continue to benefit from great advances in medical care. Sophisticated regulatory review systems have also evolved to ensure that safe and effective medicines are approved. However, these systems are not optimized in all countries. Gaps in individual regul...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-019-00055-9

    authors： O'Brien J,Lumsden RS,Diehl DH,Macdonald JC

    更新日期：2020-03-01 00:00:00

  • How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement.

    abstract：BACKGROUND:Pediatric regulations enacted in both Europe and the USA have disrupted the pharmaceutical industry, challenging business and drug development processes, and organizational structures. Over the last decade, with science and innovation evolving, industry has moved from a reactive to a proactive mode, investin...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00116-4

    authors： Severin T,Corriol-Rohou S,Bucci-Rechtweg C,An Haack K,Fuerst-Recktenwald S,Lepola P,Norjavaara E,Dehlinger-Kremer M,EFGCP Children’s Medicines Working Party.,Haertter S,Cheung SYA,IQ Pediatric Working Group.

    更新日期：2020-09-01 00:00:00

  • Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker-Driven Phase III Trial.

    abstract：BACKGROUND:The design and sample size of a phase III study for new medical technologies were historically determined within the framework of frequentist hypothesis testing. Recently, drug development using predictive biomarkers, which can predict efficacy based on the status of biomarkers, has attracted attention, and ...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00119-1

    authors： Takazawa A,Morita S

    更新日期：2020-09-01 00:00:00

  • Single-Study Approvals: Quantum of Evidence Required.

    abstract：:When does a single positive adequate and well-controlled study of a new drug meet the statutory requirement to demonstrate substantial evidence of effectiveness? The answer to this question, particularly with respect to new molecular entities, has been of considerable debate since 1962 when the requirement that new dr...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-019-00103-4

    authors： Sasinowski FJ,Butler ML

    更新日期：2020-05-01 00:00:00

  • Responsibilities of Data Monitoring Committees: Consensus Recommendations.

    abstract：BACKGROUND:A data monitoring committee (DMC) has special responsibilities for protecting the safety of clinical trial participants. Few guidance documents are available that address the operations and mechanics of establishing, serving on, or reporting to a DMC. This article provides a practical guide to sponsors, inst...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479016646812

    authors： Bierer BE,Li R,Seltzer J,Sleeper LA,Frank E,Knirsch C,Aldinger CE,Levine RJ,Massaro J,Shah A,Barnes M,Snapinn S,Wittes J

    更新日期：2016-09-01 00:00:00

  • Evolving Clinical Data Strategies and Tactics in Response to Digital Transformation.

    abstract：BACKGROUND:Contending with a continuously expanding volume and variety of clinical data poses challenges and opportunities for the industry and clinical data management organizations. METHODS:Tufts CSDD conducted an online survey aimed at further quantifying and understanding the magnitude and impact that expanded dat...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00213-4

    authors： Harper B,Wilkinson M,Indupuri R,Rocchio S,Getz K

    更新日期：2020-09-14 00:00:00

  • An Assessment of Concerns Regarding New Regulatory Guidance for Combination Products: A Review of the Submissions Made to the FDA Regarding Their Proposed Draft New Guidance on Human Factors Studies for a Combination Product in an Abbreviated New Drug App

    abstract：BACKGROUND:The US Food and Drug Administration (FDA) put out a call for comments on new draft guidance for industry "Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA." This call for comments elicited 7 submissions from various organization...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章,评审

    doi：10.1177/2168479018775659

    authors： Lance PT,Greenaway RV,Edwards B

    更新日期：2019-03-01 00:00:00

  • Adaptive Design: Results of 2012 Survey on Perception and Use.

    abstract：:Adaptive designs are increasingly used in clinical trials. The Drug Information Association's Adaptive Design Scientific Working Group (ADSWG) works to foster collaboration among regulatory agencies, academia, and pharmaceutical and biotech companies to further the science of adaptive clinical development. The ADSWG S...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479014522468

    authors： Morgan CC,Huyck S,Jenkins M,Chen L,Bedding A,Coffey CS,Gaydos B,Wathen JK

    更新日期：2014-07-01 00:00:00

  • A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward?

    abstract：:A universal framework for the evaluation of the benefit-risk assessment of medicines during development by pharmaceutical companies and in the regulatory review by regulatory authorities is considered of value, as it would result in the systematic structured approach to support transparency in decision making. Several...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479014547421

    authors： Walker S,McAuslane N,Liberti L,Leong J,Salek S

    更新日期：2015-01-01 00:00:00